Leczyme : A New Candidate Drug for Cancer Therapy

Sialic acid-binding lectin (SBL), isolated from oocytes of Rana catesbeiana, is leczyme and has both lectin and ribonuclease (RNase) activities. A remarkable antitumor effect of SBL has also been reported. SBL agglutinates various kinds of tumor cells but not normal cells. SBL agglutination activity...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2014-01, Vol.2014 (2014), p.1-10
Main Authors: Tatsuta, Takeo, Sugawara, Shigeki, Takahashi, Kohta, Ogawa, Yukiko, Hosono, Masahiro, Nitta, Kazuo
Format: Article
Language:English
Subjects:
Amino Acid Sequence
Amphibian Proteins - chemistry
Amphibian Proteins - pharmacology
Amphibian Proteins - therapeutic use
Animals
Antimitotic agents
Antineoplastic agents
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Biomedical research
Cancer
Cancer therapies
Carbohydrates
Cell Membrane - drug effects
Cell Membrane - metabolism
Colleges & universities
Cytotoxicity
Deoxyribonucleic acid
DNA
Drug Screening Assays, Antitumor
Drug therapy
Health aspects
Lectins
Lectins - chemistry
Lectins - pharmacology
Lectins - therapeutic use
Molecular Sequence Data
Neoplasms - drug therapy
Pharmaceuticals
Proteins
Rana catesbeiana
Review
Ribonucleases - chemistry
Ribonucleases - pharmacology
Ribonucleases - therapeutic use
Senescence
Signal transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sialic acid-binding lectin (SBL), isolated from oocytes of Rana catesbeiana, is leczyme and has both lectin and ribonuclease (RNase) activities. A remarkable antitumor effect of SBL has also been reported. SBL agglutinates various kinds of tumor cells but not normal cells. SBL agglutination activity is not affected by mono- or oligosaccharides. However, SBL-induced agglutination and antitumor effects are inhibited by sialomucin but not asialomucin. In addition, SBL has very little effect on sialidase-treated cells. SBL causes cancer-selective induction of apoptosis by multiple signaling pathways, which target RNA. Synergistic antitumor effects with other molecules, such as tumor necrosis factor-related apoptosis ligand (TRAIL) and interferon-γ (IFN-γ), have been reported. Thus, SBL may be a novel candidate molecule for anticancer drug development. Sialoglycoconjugates on the tumor cell surface may be associated with lectin activity and antitumor effects of SBL. We review the properties of SBL, particularly its lectin, RNase, and antitumor activities, and comprehensively examine the potential application of SBL for clinical purposes.
ISSN:2314-6133
2314-6141
DOI:10.1155/2014/421415